Increasing evidence suggests that PD-L1 protein degradation effectively promotes cancer immunotherapy (Table 1) and the combination therapy significantly enhances this event (Table 2), which provides a potential strategy to increase the response rates of PD-1/PD-L1 blockade in cancer immunotherapy. The gene discussed is CD274; the disease is cancer.